Haemonetics Corporation

Good day, and thank you for standing by. Welcome to the second quarter 2025 Humanetics Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 111 on your telephone. You will then hear an automated message advising you that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Olga Gayet.

Please go ahead. Good morning, everyone.

Thank you for joining us for Human EdX second quarter fiscal year 2025 conference call and webcast. I'm joined today by Chris Simon, our CEO, and James Durecka, our CFO. This morning, we posted our second quarter fiscal year 2025 results to our Investor Relations website, along with our fiscal year 2025 guidance. Before we begin, just a quick reminder that all revenue growth rates discussed today are organic, unless specified otherwise, and exclude the impact of currency fluctuation and acquisition. Our organic revenue growth guidance for fiscal year 2025 incorporates 15 weeks of revenue from Opsense due to the acquisition closing date being in December 2023. We'll also refer to other non-GAAP financial measures to help investors understand Humanitics' ongoing business performance. Please note that these measures exclude certain charges and income items. For a full list of excluded items, reconciliations to our GAAP results, and comparisons with the prior year periods, Please refer to our second quarter fiscal year 2025 earnings release available on our website. Our remarks today include forward-looking statements, and our actual results may differ materially from anticipated results. Factors that may cause our results to differ include those referenced in Safe Harbor's statement in today's earnings release and in our usual SSE filings. We do not undertake any obligation to update these forward-looking statements. And now, I'd like to turn it over to Chris.